This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Myocardial infarction (MI)	Tissue inhibitor of metalloproteinases 3 (TIMP3)	<p>Pig studies suggest recombinant TIMP3-containing, biodegradable hydrogels could help reduce damage following MI. After MI, matrix metalloproteinases are released and contribute to adverse remodeling. In a pig model of MI, injection of recombinant TIMP3-containing, biodegradable hydrogels into the left ventricle decreased left ventricle inflammatory markers, regional infarct expansion and left ventricular dilation and ejection fraction—a measure of cardiac function—compared with injection of either hydrogels without recombinant TIMP3 or saline. Next steps could include studies carried out over longer observational periods and dose-titration studies of recombinant TIMP3 in the hydrogel.</p> <p>SciBX 7(9); doi:10.1038/scibx.2014.258 Published online March 6, 2014</p>	Patent application filed; unavailable for licensing	<p>Eckhouse, S.R. <i>et al. Sci. Transl. Med.</i>; published online Feb. 12, 2014; doi:10.1126/scitranslmed.3007244 Contact: Francis G. Spinale, University of South Carolina School of Medicine, Charleston, S.C. e-mail: cvctrc@uscmed.sc.edu</p>